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Abstract 
The incidence of prostate cancer (PC) accompanying periodontal disease (PD) is anticipated to increase 
due to population aging. The aim of this study was to determine the association between PD and PC 
using data in the National Health Insurance Service–Health Examinee Cohort (NHIS-HEC). A random 
stratified sample of 187,934 South Koreans was collected from the NHIS database from 2002 to 2013. 
We assessed the relationship between PD and PC while adjusting for potential confounding factors (sex, 
age, household income, insurance status, residence area, hypertension, diabetes mellitus, cerebral 
infarction, angina pectoris, myocardial infarction, smoking status, alcohol intake, and regular exercise). 
The overall incidence of PC with PD among those aged 40 years and older was 0.28% (n = 531). In the 
multivariate Cox proportional-hazard regression analysis with adjustment for confounding factors, PD 
was associated with a 14% higher risk of PC (HR = 1.14, 95% CI = 1.01–1.31, P = 0.042). The findings of 
this study suggest that PD is significantly and positively associated with PC. Further studies are required 
to identify the mechanisms underlying the links between PD and PC. 
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Introduction 
Periodontal disease (PD) is a chronic bacterial 
and inflammatory disease whose prevalence is 
reportedly as high as 90% [1, 2]. PD can routinely 
injure or damage both oral soft and hard tissues such 
as gingiva, cementum, periodontal ligament, and 
supporting alveolar bone, and it is the primary risk 
factor for tooth loss in adults [3, 4]. Recent studies 
have also found PD to be associated with 
cardiovascular disease, pregnancy disease, chronic 
respiratory disease, diabetes mellitus, and erectile 
dysfunction [5-8]. Oral pathologic bacteria are not 
only a dominant risk factor for PD, but are also a risk 
factor for major systemic diseases due to several 
mechanisms involving modulation of the 
inflammatory pathway and systemic immunity [9].  
Chronic inflammation caused by bacterial 
infection has been reported as one of the main factors 
underlying the development of cancer [10]. 
Cumulative studies have demonstrated the relation 
between oral bacteria and initiation or progression of 
systemic cancer [11]. In particular, oral pathologic 
bacteria such as Aggregatibacter actinomycetemcomitans, 
Fusobacterium nucleatum, Tannerella forsythia, 
Treponema denticola, and Porphyromonas gingivalis are 
significantly positively associated with oral, 
pancreatic, and gastrointestinal cancers [12, 13]. Oral 
pathologic bacteria can either up- or down-regulate 








including interleukin (IL)-1β, IL-6, tumor necrosis 
factor (TNF)-α, and C-reactive protein, resulting in 
oral pathologic bacteria being able to affect the oral 
and systemic immune systems of the body and also 
induce oncogenic responses [14, 15]. 
Prostate cancer (PC) is the most-common cancer 
in men in the United States and Europe. While PC is 
only the fifth-most-common diagnosed malignancy 
and the seventh leading cause of cancer death among 
men in South Korea, the rapid aging of the Korea 
population and the increasing prevalence of obesity 
have resulted in a steep increase in the incidence of 
PC recently. PD is apparently associated with oral 
bacterial dysbiosis and systemic immune responses, 
but the role of oral pathogenic bacteria in 
carcinogenesis remains unclear. Also, a direct 
correlation between PD and PC is still unclear and 
controversial. While numerous cross-sectional and 
cohort studies have identified associations between 
PD and facial cancers, especially those of the oral and 
neck, there have been very few well-designed studies 
with stratified longitudinal cohorts comparing PD 
and PC [16, 17]. Our aim was therefore to determine 
whether there is a connection between PD and PC 
using data from a South Korean nationwide 
population based on National Health Insurance 
Service–Health Examinee Cohort (NHIS-HEC). 
Materials and Methods 
Study design and data collection 
In South Korea, patients in the NHIS are 
required to pay approximately 30% of their total 
medical expenses when they use medical facilities, 
with the medical providers submitting claims for the 
remaining 70%. This has resulted in the NHIS having 
access to an enormous database (DB) of more than one 
trillion cases involving the entire Korean population 
of 51 million covering the past decade. This DB 
includes information on individual qualification 
criteria, insurance coverage and payouts, medical and 
dental records, health checkups, rare incurable 
diseases, systemic cancer, and long-term-care 
insurance services. The NHIS program is designed for 
the heads of households, household members aged 40 
years or older, and workplace subscribers who receive 
regular health checkup examinations once every 2 
years, which include a self-reported questionnaire on 
smoking, alcohol consumption, and exercise. 
A random stratified sample of 514,866 South 
Koreans was collected from the NHIS DB by the NHIS 
Big Data Steering Department, which is conducting 
1,476-stage simple sampling based on sex, age, and 
household income level for the 12 years from 2002 to 
2013. After performing stratified sampling of the data 
for 2002, the data in the cohort DB are maintained to 
2013 except when sample objects become ineligible 
due to death or emigration. To compensate for the 
natural reduction in the population data over time, 
neonatal samples are added yearly in order to 
maintain the sample size, making this a semidynamic 
cohort. All personal information and identification 
numbers were deleted prior to the analysis, and a 
computer-generated random number was allocated to 
each sample. This study conformed to the STROBE 
guidelines for reporting observational studies 
(www.strobe-statement.org) and was approved by 
the Institutional Review Board, Daejeon Dental 
Hospital, Wonkwang University (approval no. 
W1702/004-001). 
Identification of sociodemographic factors 
Potential confounding sociodemographic factors 
of PD and PC were assessed from the NHIS-HEC DB: 
sex, age (4 groups: those aged 40–69 years in 10-year 
intervals, and those aged ≥70 years), household 
income (5 groups: 41 groups were divided into 5 
quintiles based on the insurance fee imposed on each 
household, with the Medical Aid Program [MAP] 
group corresponds to the first quintile), insurance 
status (3 groups: those in the MAP and those in the 
NHIS, where the NHIS group included both 
self-employed and employees), and residence area (2 
groups: with a cutoff of 50,000 residents). 
Identification of comorbidity 
Patients who were diagnosed with hypertension, 
diabetes mellitus, and cardiovascular disease prior to 
2002 were excluded, and the following 
lifestyle-related comorbidities present from 2002 to 
2013 were diagnosed by medical doctors: 
hypertension (Korean Classification of Diseases, 6th 
revision [KCD-6] codes I10 and I15, corresponding to 
International Classification of Diseases, 10th revision 
[ICD-10-CM] codes I10 and I15), diabetes mellitus 
(KCD-6 codes E10–E14, corresponding to ICD-10-CM 
codes E10–E14), cerebral infarction (KCD-6 codes 
I63–I66, corresponding to ICD-10-CM codes I63–I66), 
angina pectoris (KCD-6 codes I20, corresponding to 
ICD-10-CM codes I20), and myocardial infarction 
(KCD-6 codes I21 and I22, corresponding to 
ICD-10-CM codes I21 and I22). To increase the 
validity of the assessment in comorbidities diagnoses, 
we only included patients with comorbidities who 
have been diagnosed at least twice during the period 
from 2002 to 2013.  
Identification of patients with prostate cancer 
97% of cancer patients are fully or partially 
covered by NHI and all cancer patients are registered 




in NHIS and Health Insurance Review and 
Assessment Service (HIRA) DB. Therefore, this study 
performed that PC diagnostic and prescription codes 
were obtained based on the NHIS and HIRA. Patients 
who were diagnosed with cancer prior to 2002 and 
aged <40 years were excluded according to 
self-reported questionnaire information in the NHIS 
regular health check-up examination. We selected 
patients who had been newly diagnosed with PC 
(KCD-6 codes C61; corresponding to ICD-10-CM 
codes C61) by medical oncologists and urologists 
from 2002 to 2013 and the date of which cancer was 
first diagnosed was assigned as the index date. 
Identification of patients with periodontal 
disease 
This study involved adult patients who were 
aged ≥40 years and diagnosed with acute 
periodontitis, chronic periodontitis, periodontosis, 
other PD, and unspecified PD (KCD-6 codes K05.2 to 
K05.6, corresponding to ICD-10-CM codes K05.2 to 
K05.6) prior to the index date between 2002 and 2013. 
The patients who were diagnosed as acute and 
chronic gingivitis (KCD-6 codes K05.0 to K05.1, 
corresponding to ICD-10-CM codes K05.0 to K05.1) 
were excluded as a reversible inflammatory PD. To 
increase the validity of the assessment of PD 
diagnoses, we only included patients with PD who 
have been diagnosed at least twice with a specific PD 
related-disorder during the period from 2002 through 
2013. Clinical and radiographic diagnoses of PD were 
based on measurements of the amount of bleeding on 
probing, probing depth (measured between the 
gingival crest margin and the base of the apical 
lesion), clinical attachment level (measured between 
the cementoenamel junction and the base of the apical 
lesion), gingival inflammation, and radiographic 
alveolar bone loss according to criteria of the Centers 
for Disease Control and Prevention/American 
Academy of Periodontology case definitions by local 
dentists or periodontists [18, 19]. 
Statistical analysis 
The chi-square test was used to identify 
significant differences in categorical cohort data for 
sociodemographic factors (sex, age, household 
income, insurance status, and residence area), 
comorbidities (hypertension, diabetes mellitus, 
cerebral infarction, angina pectoris, and myocardial 
infarction), self-reported questionnaire (smoking 
status, day’s smoking, alcohol intake habits, one-time 
alcohol intake, and regular exercise), and incidence of 
PC with PD. We calculated hazard ratios (HRs) with 
95% confidence intervals (CIs) using multivariate Cox 
proportional-hazards regression models while 
adjusting for sociodemographic factors, 
comorbidities, smoking status, alcohol intake, and 
regular exercise. The cumulative incidence of PC 
with/without PD was estimated using the 
Kaplan-Meier method and compared with the 
log-rank test. In all assessments performed in this 
study, P < 0.05 was considered statistically significant 
and statistical tests were two-sided. All cohort data 
used in this study were calculated using the Statistical 
Analysis System (version 9.2, SAS Institute, Cary, NC, 
USA) by the Department of Health Insurance 
Research, Ilsan Hospital, NHIS. 
Results 
Incidence of prostate cancer patients with 
periodontal disease 
Fig. 1 shows a cohort flow chart for the inclusion 
and exclusion of the study participants. Among the 
total cohort of 514,866 people, 326,932 (Female and 
cancer history) were excluded from the study and 
187,934 (18.3%) males and aged ≥40 years were 
recruited. We enrolled 934 subjects who were 
diagnosed with PC, comprising 531 PD patients 
(56.9%) and 403 Non-PD patients (43.1%). Those aged 
60–69 years (n = 398) accounted for 42.6% of the 
surveyed subjects, while 361 (38.7%) were in the fifth 
quintile of household income, 927 (99.3%) were in the 
NHIS, and 782 (83.7%) lived in urban areas (Table 1). 
 
Table 1. Baseline characteristics of the population included in the 
National Health Insurance Service–Health Examinee Cohort 
(NHIS-HEC) according to prostate cancer (PC) patients 
with/without periodontal disease (PD). 
Characteristics PD (n, %) Non-PD (n, %) Pa 
Total 531 403  
Age group (years)    
 40–49 48 (9.0) 45 (11.2) <0.001 
 50–59 139 (26.2) 98 (24.3)  
 60–69 246 (46.3) 152 (37.7)  
 ≥70 98 (18.5) 108 (26.8)  
Household incomeb    
First quintile 49 (9.2) 70 (17.4) <0.001 
 Second quintile 66 (12.4) 56 (13.9)  
 Third quintile 87 (16.4) 68 (16.9)  
 Fourth quintile 110 (20.7) 67 (16.6)  
 Fifth quintile 219 (41.3) 142 (35.2)  
Insurance status    
 MAP 4 (0.8) 3 (0.7) <0.001 
 NHIS (self-employed) 293 (55.2) 206 (51.1)  
 NHIS (employees) 234 (44.0) 194 (48.2)  
Residence areac    
 Urban 466 (87.8) 316 (78.4) <0.001 
 Rural 65 (12.2) 87 (21.6)  
Abbreviations: MAP: Medical Aid Program. 
aP values were calculated using the chi-square test; boldface denotes statistical 
significance (P < 0.05). 
bDivided into five quintiles based on the insurance fee imposed on each household, 
with the MAP group classed into the first quintile. 
cClassified with a cutoff of 50,000 residents. 
 





Figure 1. Flow chart of the inclusion and exclusion of participants in the National Health Insurance Service– Health Examinee Cohort during 2002–2013; PD: 
periodontal disease. 
 
Results of comorbidity and regular health 
check-up examination 
Although comorbid disease (hypertension, 
diabetes mellitus, cerebral infarction, angina pectoris, 
and myocardial infarction) showed higher incidence 
of PD patients compared with Non-PD patients, only 
myocardial infarction was statistically significantly 
higher in PD patients compared with Non-PD 
patients (P < 0.001). In the questionnaire survey, 
smoking and exercise status were only statistically 
significant between PD patients and Non-PD patients 
(P < 0.001; Table 2). 
Association of prostate cancer with 
periodontal disease 
In the multivariate Cox regression analysis with 
adjustment for sociodemographic factors, 
comorbidities, smoking status, alcohol intake, and 
regular exercise, PD was associated with a 14% higher 
risk of PC (HR = 1.14, 95% CI = 1.01–1.31, P = 0.042). 
In addition, using the adjusted Kaplan-Meier curve 
with the number of subjects at risk, we found that the 
incidence of PC with PD was significantly higher than 
that of PC without PD (P < 0.001; Fig. 2). The presence 
of both PC and PD was significantly positively 
correlated with current smoking (HR = 1.68, 95% CI = 
1.52–1.85, P < 0.001), smoking ≥20 cigarettes a day 
(HR = 1.20, 95% CI = 1.04–1.40, P = 0.015), consuming 
alcohol every day (HR = 1.17, 95% CI = 1.09–1.25, P < 
0.001), and consuming ≥1 bottle of beer (360 ml) daily 
(HR = 1.08, 95% CI = 1.03–1.13, P < 0.001; Table 3). 
 
Table 2. Results of comorbidity and regular health check-up 
examination 
Characteristics PD (n, %) Non-PD (n, %) Pa 
Comorbid disease   
Hypertension 329 (62.0%) 246 (61.0%) 0.776 
Diabetes mellitus 194 (36.5%) 133 (33.0%) 0.262 
Cerebral infarction 102 (19.2%) 61 (15.1%) 0.104 
Angina pectoris 22 (4.1%) 13 (3.2%) 0.465 
Myocardial infarction 142 (26.7%) 67 (16.6%) <0.001 
Self-reported questionnaire   
Smoking statusb    
 Yes 371 (69.9%) 133 (33.0%) <0.001 
 No 160 (30.1%) 270 (67.0%)  
Day’s smoking    
 <20 piece 334 (90.0%) 112 (84.2%) 0.072 
 ≥20 piece 37 (10.0%) 21 (15.8%)  
Alcohol intake habits    
 No drinking 259 (48.8%) 207 (51.4%) 0.153 
 1–4 times/week 237 (44.6%) 159 (39.5%)  
 Almost every day 35 (6.6%) 37 (9.1%)  
One-time alcohol intake    
 <1 bottle of beer (360ml) 237 (87.1%) 170 (86.7%) 0.900 
 ≥1 bottle of beer (360ml) 35 (12.9%) 26 (13.3%)  
Regular exercise    
 No 244 (46.0%) 229 (56.8%) <0.001 
 1–4 times/week 209 (39.4%) 108 (26.8%)  
 ≥5 times/week 78 (14.6%) 66 (16.4%)  
Abbreviations: PD: periodontal disease 
aP values were calculated using the chi-square test; boldface denotes statistical 
significance (P < 0.05). 
bSubjects were currently not smoking, or had smoked <100 cigarettes were 
classified as non-smokers, while the other subjects were classified as smokers. 
 





Figure 2. Cumulative incidence of prostate cancer with/without periodontal disease (PD) was estimated using the Kaplan-Meier method and compared using the 
log-rank test. Incidence of prostate cancer patients with PD was higher and significantly different from prostate cancer patients without PD (P < 0.001). 
 
Table 3. Association of PC patients with PD in multivariate Cox 
proportional-hazard regression analysis with adjustment for 
confounding factors. 
Characteristics HR 95% CI Pa 
Age group (ref: 40–49 years) 
 50–59  2.21 1.92–2.55 <0.001 
 60–69  5.86 5.14–6.68 <0.001 
 ≥70 14.31 12.57–16.30 <0.001 
Household income (ref: First quintile) 
 Second quintile 1.33 1.11–1.58 <0.001 
 Third quintile 1.16 0.99–1.35 0.066 
 Fourth quintile 1.12 0.99–1.28 0.069 
 Fifth quintile 1.13 0.97–1.31 0.118 
Insurance status (ref: MAP) 
NHIS (self-employed) 0.42 0.19–0.91 0.026 
NHIS (employees) 0.46 0.21–0.99 0.045 
Residence area (ref: Urban) 
Rural 0.97 0.80–1.16 0.713 
Smoking status (ref: No)    
 Yes 1.68 1.52–1.85 <0.001 
Day’s smoking (ref: <20 piece)    
≥20 piece 1.20 1.04–1.40 0.015 
Alcohol intake habits (ref: No)    
1–4 times/week 0.94 0.91–0.97 <0.001 
 Almost every day 1.17 1.09–1.25 <0.001 
1-time alcohol (ref: <1 bottle)    
 ≥1 bottle (360ml) 1.08 1.03–1.13 0.001 
Regular exercise (ref: No) 
1–4 times/week 1.00 0.97–1.03 0.858 
≥5 times/week 0.83 0.78–0.89 <0.001 
Periodontal disease 1.14 1.01–1.31 0.042 
Abbreviations: PD: periodontal disease; HR: hazard ratio; CI: confidence interval. 
aBoldface denotes statistical significance (P < 0.05). 
Multivariate regression analysis adjusted for sex, age, household income, insurance 
status, residence area, hypertension, diabetes mellitus, cerebral infarction, angina 
pectoris, myocardial infarction, smoking status, alcohol intake, and regular 
exercise. 
Discussion 
PD is the most-common inflammatory disease, 
and many of its known risk factors – sex, age, 
smoking, obesity, hypertension, and diabetes mellitus 
– are also considered to be risk factors for systemic 
cancer [20]. We observed that the risk of PC was 
significantly positively correlated with age ≥70 years, 
lower income, being registered with the MAP, 
myocardial infarction, heavy smoking, high alcohol 
consumption, and less exercise. The data was not 
statistically significant except second quintile, but the 
lower the household income, the higher the risk for 
PC. This can be explained by the reduced accessibility 
to healthcare services and limitations of the current 
study involving PC patients who only visited clinics 
for the cancer but not for the PD. We also found that 
the incidence of PD – which is well known to be 
related to oral cancer – was also significantly positive 
associated with PC in a multivariate analysis. 
Few studies have investigated the association of 
PC with PD [21-23]. In one prospective cohort based 
on the Health Professionals Follow-Up Study it was 
found that PD was correlated with a slight but 
significant increase in the risk of systemic cancer, but 
PD was also inversely correlated with PC (HR = 0.99, 
95% CI = 0.61–1.59) and tooth loss (HR = 0.70, 95% CI 
= 0.50–0.97) [21]. Hiraki et al. [22] conducted a 
large-scale case–control study of Japanese patients, 
and reported that increased tooth loss was correlated 




with a decreased risk of PC after adjusting for 
potential confounding factors (odds ratio [OR] = 0.49, 
95% CI = 0.19–1.26, P = 0.049). In particular, the risk of 
PC was higher when more teeth were remaining, and 
this may have been due not only to the 
sociodemographic and economic characteristics of the 
studied subjects, but also to the number of teeth 
affected by PD. Unlike these studies, the NHANES I 
Epidemiologic Follow-up Study found that PD was 
associated with an elevated risk of PC (HR = 1.81, 95% 
CI = 0.76–4.34) [23]. However, that study was 
hampered by poor statistical power due to the 
smallness of the sample and also potentially by the 
smallness of any real effects. 
Both the bivariate analysis (HR = 1.60, 95% CI = 
1.40–1.83, P < 0.001; data not shown) and multivariate 
analysis (HR = 1.14, 95% CI = 1.01–1.31, P = 0.042) 
performed in the present study showed that PD was 
positively and significantly associated with PC. Both 
diseases produce generalized inflammation and 
infection in the body, and especially chronic PD has 
been shown to increase the level of prostate-specific 
antigen (PSA) that is produced primarily by epithelial 
prostate cells and is used to diagnose PC [24]. The 
PSA level is significantly higher in chronic prostatitis 
patients with PD characterized by a gingival clinical 
attachment level of ≥ 2.7 mm (10.8±7.0 ng/ml) than in 
those without such PD (5.6±3.7 ng/ml, P = 0.05) [24]. 
In addition, Alwithanani et al. [25] reported that the 
mean PSA level was significantly higher in PD 
patients regardless of the presence or absence of PC 
and the prostate symptom score, and that the PSA 
level might decrease after treating PD. There is 
accumulating evidence of proinflammatory cytokines 
such as IL-6, IL-8, IL-18, TNF-α, and C-reactive 
protein being associated with the pathogenesis of PC 
[24]. These observations may indicate the similarity of 
the etiopathogenesis of PD and PC. 
A recent systematic review found a significant 
positive relationship between PD and erectile 
dysfunction [26]. Both conditions share chronic 
inflammation and systemic endothelial dysfunction, 
which are also key mechanisms of carcinogenesis [27]. 
The invasion of oral pathological bacteria, especially 
Porphyromonas gingivalis, may induce traumatic injury 
and irritation of the epithelium and mucosa, and play 
a role in subsequent cancer progression [28, 29]. A 
nationwide population-based cohort study found that 
the risk of cancer was 1.42-fold higher (95% CI = 
1.03–2.09, P = 0.039) in patients with erectile 
dysfunction [30]. In our previous study we found a 
strong association between PD and vasculogenic 
erectile dysfunction in a nationwide population-based 
NHIS-HEC (OR = 1.53, 95% CI = 1.41–1.65, P < 0.001) 
[31]. Although the evidence is not definitive, these 
results suggest that a diagnosis of PD is associated 
with a higher risk of PC. 
Androgen deprivation therapy (ADT) is the 
most-common standard treatment for advanced PC, 
and its application is increasing rapidly [32]. 
However, many studies have suggested that ADT is 
associated with cardiovascular disease, diabetes 
mellitus, and Alzheimer’s disease, with in particular it 
being the main cause of male osteoporosis since it can 
affect almost any bone structure of the body [33, 34]. 
Male osteoporosis can result from various causes, 
including bone resorption, bone loss, and bone 
fracture, and several studies have found that PD can 
be exacerbated by systemic bone loss such as 
osteoporosis or rheumatoid arthritis [35-37]. Famili et 
al. [38] considered that patients with PC receiving 
ADT are more likely to develop PD or experience 
worsening of PD than are patients who are not on 
ADT. Although it is difficult to conclude that ADT for 
PC can induce or exacerbate PD, this observation 
should be considered when deciding whether or not 
to apply ADT to PC patients. 
This study was subject to several limitations. 
Firstly, selection bias may have been present due to its 
retrospective design and only including patients who 
visited dental clinics and hospitals and who were 
diagnosed with PD and PC [39]. Secondly, this study 
did not analyze medical and dental records, which 
restricted the ability to diagnose the severity and the 
follow-up period of PD and PC in the DB of this 
cohort. Therefore, future cohort studies should 
consider the severity and the follow-up period of PD 
and PC in the design. Finally, because the data were 
acquired from a diverse group of medical and dental 
specialties, inconsistent diagnostic criteria were likely 
to have been applied. Nevertheless, the results from 
this nationwide population-based longitudinal cohort 
study in South Korea are considered to provide 
evidence for a link between PD and PC. PD is clearly 
intimately associated with systemic inflammation and 
immune dysregulation, which are both direct and 
indirect etiological factors in systemic cancer [40, 41]. 
However, the etiological and bidirectional 
associations between PD and PC remain unclear, and 
little is known about their underlying mechanisms. 
Therefore, further investigations of the biological 
plausibility and the gathering of clinical and 
epidemiological evidence are needed to both 
strengthen and understand the association between 
PD and PC. 
Conclusion 
To our knowledge, this study is the first to 
investigate the association of PC with PD using a 
retrospective analysis of a nationwide 




population-based NHIS-HEC. In contrast to some 
previous studies, the present cohort study has shown 
that patients with PD have a significantly but slightly 
positive in patients with PC. Further studies are 
required to strengthen this hypothesis and focus on 
identifying the mechanisms underlying the links 
between PD and PC. If confirmed, this observation 
could have clinical and public health implications 
given the increasing prevalence of PD worldwide. 
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